Kiniksa's Arcalyst Growth Outlook Strengthens, Wedbush Says

MT Newswires Live07-28

Kiniksa Pharmaceuticals International (KNSA) is benefiting from continued momentum for Arcalyst, its treatment for recurrent pericarditis, a condition in which the sac around the heart becomes inflamed in repeated episodes, Wedbush Securities said Tuesday in a report.

Arcalyst's growth continues to be driven by broadening prescriber adoption, with more than 5,000 clinicians having used the therapy since launch and returning users accounting for over half of new scripts, Wedbush said.

Kiniksa shares face additional upside as Arcalyst's cash generation supports development of the company's pipeline and as newer recurrent pericarditis assets create a path for long-term expansion, the report said.

Wedbush highlighted KPL-387, Kiniksa's next-generation treatment candidate, as a "de-risked" opportunity that may strengthen the company's position in IL-1 blockade for recurrent pericarditis while improving the franchise's long-term economics

Wedbush increased its price target on Kiniksa's stock to $99 from $72 and maintained its outperform rating.

Price: 79.38, Change: +15.84, Percent Change: +24.93

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2654886871?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 23:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654886871","market":"fut","top_or_hot":-1,"title":"Kiniksa's Arcalyst Growth Outlook Strengthens, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> Kiniksa Pharmaceuticals International (KNSA) is benefiting from continued momentum for Arcalyst, its treatment for recurrent pericarditis, a condition in which the sac around the heart becomes inflamed in repeated episodes, Wedbush Securities said Tuesday in a report.</p><p>Arcalyst's growth continues to be driven by broadening prescriber adoption, with more than 5,000 clinicians having used the therapy since launch and returning users accounting for over half of new scripts, Wedbush said.</p><p>Kiniksa shares face additional upside as Arcalyst's cash generation supports development of the company's pipeline and as newer recurrent pericarditis assets create a path for long-term expansion, the report said.</p><p>Wedbush highlighted KPL-387, Kiniksa's next-generation treatment candidate, as a \"de-risked\" opportunity that may strengthen the company's position in IL-1 blockade for recurrent pericarditis while improving the franchise's long-term economics</p><p>Wedbush increased its price target on Kiniksa's stock to $99 from $72 and maintained its outperform rating.</p><p>Price: 79.38, Change: +15.84, Percent Change: +24.93</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kiniksa's Arcalyst Growth Outlook Strengthens, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKiniksa's Arcalyst Growth Outlook Strengthens, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-28 23:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Kiniksa Pharmaceuticals International (KNSA) is benefiting from continued momentum for Arcalyst, its treatment for recurrent pericarditis, a condition in which the sac around the heart becomes inflamed in repeated episodes, Wedbush Securities said Tuesday in a report.</p><p>Arcalyst's growth continues to be driven by broadening prescriber adoption, with more than 5,000 clinicians having used the therapy since launch and returning users accounting for over half of new scripts, Wedbush said.</p><p>Kiniksa shares face additional upside as Arcalyst's cash generation supports development of the company's pipeline and as newer recurrent pericarditis assets create a path for long-term expansion, the report said.</p><p>Wedbush highlighted KPL-387, Kiniksa's next-generation treatment candidate, as a \"de-risked\" opportunity that may strengthen the company's position in IL-1 blockade for recurrent pericarditis while improving the franchise's long-term economics</p><p>Wedbush increased its price target on Kiniksa's stock to $99 from $72 and maintained its outperform rating.</p><p>Price: 79.38, Change: +15.84, Percent Change: +24.93</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2654886871","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654886871","pubTimestamp":1785253237,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kiniksa Pharmaceuticals International  is benefiting from continued momentum for Arcalyst, its treatment for recurrent pericarditis, a condition in which the sac around the heart becomes inflamed in repeated episodes, Wedbush Securities said Tuesday in a report.Arcalyst's growth continues to be driven by broadening prescriber adoption, with more than 5,000 clinicians having used the therapy since launch and returning users accounting for over half of new scripts, Wedbush said.Kiniksa shares face additional upside as Arcalyst's cash generation supports development of the company's pipeline and as newer recurrent pericarditis assets create a path for long-term expansion, the report said.Wedbush highlighted KPL-387, Kiniksa's next-generation treatment candidate, as a \"de-risked\" opportunity that may strengthen the company's position in IL-1 blockade for recurrent pericarditis while improving the franchise's long-term economicsWedbush increased its price target on Kiniksa's stock to $99 fr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4505":"高瓴资本持仓","KNSA":"Kiniksa Pharmaceuticals Ltd."},"translate_title":"Wedbush 表示，Kiniksa 的 Arcalyst 增长前景增强","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KNSA":1},"content_text":"Kiniksa Pharmaceuticals International (KNSA) is benefiting from continued momentum for Arcalyst, its treatment for recurrent pericarditis, a condition in which the sac around the heart becomes inflamed in repeated episodes, Wedbush Securities said Tuesday in a report.Arcalyst's growth continues to be driven by broadening prescriber adoption, with more than 5,000 clinicians having used the therapy since launch and returning users accounting for over half of new scripts, Wedbush said.Kiniksa shares face additional upside as Arcalyst's cash generation supports development of the company's pipeline and as newer recurrent pericarditis assets create a path for long-term expansion, the report said.Wedbush highlighted KPL-387, Kiniksa's next-generation treatment candidate, as a \"de-risked\" opportunity that may strengthen the company's position in IL-1 blockade for recurrent pericarditis while improving the franchise's long-term economicsWedbush increased its price target on Kiniksa's stock to $99 from $72 and maintained its outperform rating.Price: 79.38, Change: +15.84, Percent Change: +24.93","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.0","shortVersion":"4.47.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2654886871","isCrawlerRequest":true}